首頁 > 市場調查報告書 > 製藥

骨疾病

全球銀屑病關節炎治療市場研究報告 - 2023-2030 年行業分析、規模、份額、增長、趨勢和預測

市場調查報告書

商品編碼

1267307

全球銀屑病關節炎治療市場研究報告 - 2023-2030 年行業分析、規模、份額、增長、趨勢和預測

Global Psoriatic Arthritis Therapeutics Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

出版日期: 2023年04月01日 | 出版商:

Value Market Research | 英文 175 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球對銀屑病關節炎治療藥物的需求估計將從 2022 年的 15.24 美元增長到 2030 年的約 38,390 億美元，在 2023-2030 年調查期間的複合年增長率為 12.24%。

銀屑病關節炎藥物可治療銀屑病關節炎，一種影響某些銀屑病患者的關節炎，是一種稱為銀屑病的皮膚病，會產生覆蓋著銀色鱗屑的紅色皮膚區域。. 一般來說，關節炎通常是在牛皮癬出現後才被診斷出來的。然而，有時關節問題先於皮疹。當免疫系統開始針對健康細胞和組織時，就會出現這種情況。關節炎症和皮膚細胞的過度生成是由不適當的免疫反應引起的。

市場動態：

隨著關節炎患者數量的增加，關節炎治療藥物的市場可能會擴大。不健康的生活方式，如過度飲酒和吸煙，也被認為是發展銀屑病關節炎的危險因素，這可能會擴大銀屑病關節炎治療藥物的市場。肥胖是推動銀屑病關節炎發展的主要因素之一，可能會增加治療藥物的市場增長。此外，創新療法的發現預計將推動銀屑病關節炎療法市場的發展。高昂的治療成本、嚴格的監管批准和藥物副作用等因素可能會阻礙銀屑病關節炎治療市場的增長。

這份研究報告描述了波特的五力模型、市場吸引力分析和價值鏈分析。這些工具可幫助您清楚地了解您的行業結構並評估您在全球範圍內的競爭吸引力。此外，這些工具還提供了對全球銀屑病關節炎治療市場各個部分的全面評估。銀屑病關節炎治療行業的發展和趨勢為這項研究提供了一種整體方法。

市場細分：

本節提供有關銀屑病關節炎治療市場報告的國家和地區細分的詳細數據，從而幫助策略師確定其各自產品或服務的目標人群以及未來的機會。幫助您獲得

按藥物類別

腫瘤壞死因子抑製劑
白細胞介素抑製劑
Pde4 抑製劑
其他

按給藥途徑

口語
腸外
專題

按分銷渠道

醫院藥房
零售藥房
在線藥店

按地區分析：

本節涵蓋區域展望，重點介紹北美、歐洲、亞太地區、拉丁美洲、中東和非洲對銀屑病關節炎治療藥物市場的當前和未來需求。此外，它還關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的綜合概況和全球競爭格局的詳細視圖。銀屑病關節炎藥物市場的主要參與者是 AbbVie Inc.、Janssen Pharmaceutical NV、Novartis AG、Amgen Inc.、Celgene Corporation、Eli Lilly and Company、Bristol Myers Squibb、UCB S.A. 主要併購、競爭格局的整體視圖，包括各種戰略發展，例如未來能力、合作夥伴關係、財務概況、聯盟、新產品開發、新產品發布和其他發展。

內容

第一章前言

報告內容
- 目的
- 目標受眾
- USP（獨特的銷售建議）及其提供的內容
調查範圍
調查方法
- 市場調研流程
- 市場研究方法

第 2 章執行摘要

市場亮點
全球市場概況

第 3 章銀屑病關節炎藥物 - 行業分析

簡介 - 市場動態
市場驅動力
市場製約因素
機會
行業趨勢
波特的五力分析
市場吸引力分析
- 按藥物類別進行的市場吸引力分析
- 按給藥途徑進行的市場吸引力分析
- 按分銷渠道進行的市場吸引力分析
- 市場吸引力分析：按地區

第四章價值鏈分析

價值鏈分析
原材料分析
- 原材料清單
- 原材料製造商名單
- 主要原材料價格走勢
潛在買家名單
營銷渠道
- 直接營銷
- 間接營銷
- 市場發展趨勢

第 5 章 COVID-19 爆發的影響分析

第 6 章全球銀屑病關節炎藥物市場分析：按藥物類別分類

按藥物類別匯總
過去和未來的數據
按藥物類別分析
腫瘤壞死因子抑製劑
白細胞介素抑製劑
PDE4抑製劑
其他

第 7 章銀屑病關節炎藥物給藥途徑的全球市場分析

按給藥途徑匯總
過去和未來的數據
給藥途徑分析
口語
腸外
專題

第 8 章銀屑病關節炎藥物分銷渠道的全球市場銷售分析

按分銷渠道概述
過去和未來的數據
按分銷渠道分析
醫院藥房
零售藥房
在線藥店

第9章按地區分列的銀屑病關節炎藥物的全球市場銷售分析

按地區進行的銷售前景分析
介紹銷售分析
北美銷售分析
- 概覽、歷史和預測銷售分析
- 北美各部門的銷售分析
- 北美銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史和預測銷售分析
- 按細分市場進行的歐洲銷售分析
- 按國家/地區劃分的歐洲銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 意大利銷售分析
- 俄羅斯銷售分析
- 其他歐洲銷售分析
亞太地區銷售分析
- 概覽、歷史和預測銷售分析
- 亞太地區各部門的銷售分析
- 亞太國家/地區銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本的銷售分析
- 韓國銷售分析
- 澳大利亞銷售分析
- 其他亞太地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史和預測銷售分析
- 拉丁美洲各部門的銷售分析
- 拉丁美洲國家/地區的銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利的銷售分析
- 其他拉丁美洲銷售分析
中東和非洲銷售分析
- 概覽、歷史和預測銷售分析
- 中東和非洲各細分市場的銷售額分析
- 中東和非洲國家/地區的銷售分析
- 沙特阿拉伯銷售分析
- 阿聯酋銷售分析
- 以色列銷售分析
- 南非銷售分析
- 其他中東和非洲銷售分析

第10章：銀屑病關節炎藥物公司的競爭格局

銀屑病關節炎藥物市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他擴展

第11章公司簡介

前 10 名公司的市場份額分析
市場集中度
艾伯維公司
- 公司簡介
- 企業收入
- 產品介紹
- 近期趨勢
楊森製藥公司
- 公司簡介
- 企業收入
- 產品介紹
- 近期趨勢
諾華公司
- 公司簡介
- 企業收入
- 產品介紹
- 近期趨勢
安進公司
- 公司簡介
- 企業收入
- 產品介紹
- 近期趨勢
新基公司
- 公司簡介
- 企業收入
- 產品介紹
- 近期趨勢
禮來公司
- 公司簡介
- 企業收入
- 產品介紹
- 近期趨勢
百時美施貴寶
- 公司簡介
- 企業收入
- 產品介紹
- 近期趨勢
UCB S.A.
- 公司簡介
- 企業收入
- 產品介紹
- 近期趨勢

注意：在公司簡介、財務細節、近期發展等方面，基於可用信息，私人控股公司可能不包括在內。

簡介目錄圖表

Product Code: VMR11219987

The global demand for Psoriatic Arthritis Therapeutics Market is presumed to reach the market size of nearly USD 38.39 BN by 2030 from USD 15.24 BN in 2022 with a CAGR of 12.24% under the study period 2023 - 2030.

Psoriatic arthritis therapeutics to treat psoriatic arthritis, a kind of arthritis that affects certain psoriasis patients, is a skin condition known as psoriasis that creates red regions of skin coated in silvery scales. Typically, psoriatic arthritis is not diagnosed until after psoriasis has developed in a patient. Occasionally, though, joint problems may develop before skin rashes. This condition manifests when the immune system starts targeting healthy cells and tissue. Joint inflammation and excessive skin cell creation result from an inappropriate immunological response.

Market Dynamics:

The rising incidence of psoriatic arthritis patients may boost the market for psoriatic arthritis therapeutics. Factors such as an unhealthy lifestyle with excessive alcohol use and smoking can also be recognized as risk factors for developing psoriatic arthritis, hence growing the market for psoriatic arthritis therapeutics. Obesity is one of the primary factors that might accelerate the incidence of psoriatic arthritis, therefore expanding the market growth of treatment. Furthermore, the discovery of innovative therapy approaches is projected to propel the psoriatic arthritis therapeutics market forward. Factors such as high treatment costs, demanding regulatory approval, and drug side effects may impede the growth of the Psoriatic arthritis therapeutics market.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of psoriatic arthritis therapeutics. The growth and trends of psoriatic arthritis therapeutics industry provide a holistic approach to this study.

Market Segmentation:

This section of the psoriatic arthritis therapeutics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

TNF Inhibitors
Interleukin Inhibitors
Pde4 Inhibitors
Others

By Route Of Administration

Oral
Parenteral
Topical

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Regional Analysis:

This section covers the regional outlook, which accentuates current and future demand for the Psoriatic Arthritis Therapeutics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the psoriatic arthritis therapeutics market include AbbVie Inc., Janssen Pharmaceutical NV, Novartis AG, Amgen Inc., Celgene Corporation, Eli Lilly and Company, Bristol Myers Squibb, UCB S.A. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . PSORIATIC ARTHRITIS THERAPEUTICS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Class
- 3.7.2 Market Attractiveness Analysis By Route Of Administration
- 3.7.3 Market Attractiveness Analysis By Distribution Channel
- 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL PSORIATIC ARTHRITIS THERAPEUTICS MARKET ANALYSIS BY DRUG CLASS

6.1 Overview by Drug Class
6.2 Historical and Forecast Data
6.3 Analysis by Drug Class
6.4 TNF Inhibitors Historic and Forecast Sales by Regions
6.5 Interleukin Inhibitors Historic and Forecast Sales by Regions
6.6 PDE4 Inhibitors Historic and Forecast Sales by Regions
6.7 Others Historic and Forecast Sales by Regions

7 . GLOBAL PSORIATIC ARTHRITIS THERAPEUTICS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

7.1 Overview by Route Of Administration
7.2 Historical and Forecast Data
7.3 Analysis by Route Of Administration
7.4 Oral Historic and Forecast Sales by Regions
7.5 Parenteral Historic and Forecast Sales by Regions
7.6 Topical Historic and Forecast Sales by Regions

8 . GLOBAL PSORIATIC ARTHRITIS THERAPEUTICS MARKET SALES ANALYSIS BY DISTRIBUTION CHANNEL

8.1 Overview by Distribution Channel
8.2 Historical and Forecast Data
8.3 Analysis by Distribution Channel
8.4 Hospital Pharmacies Historic and Forecast Sales by Regions
8.5 Retail Pharmacies Historic and Forecast Sales by Regions
8.6 Online Pharmacies Historic and Forecast Sales by Regions

9 . GLOBAL PSORIATIC ARTHRITIS THERAPEUTICS MARKET SALES ANALYSIS BY GEOGRAPHY

9.1. Regional Outlook Sales Analysis
9.2. Introduction Sales Analysis
9.3. North America Sales Analysis
- 9.3.1. Overview, Historic and Forecast Sales Analysis
- 9.3.2. North America By Segment Sales Analysis
- 9.3.3. North America By Country Sales Analysis
- 9.3.4. United State Sales Analysis
- 9.3.5. Canada Sales Analysis
- 9.3.6. Mexico Sales Analysis
9.4. Europe Sales Analysis
- 9.4.1. Overview, Historic and Forecast Sales Analysis
- 9.4.2. Europe by Segment Sales Analysis
- 9.4.3. Europe by Country Sales Analysis
- 9.4.4. United Kingdom Sales Analysis
- 9.4.5. France Sales Analysis
- 9.4.6. Germany Sales Analysis
- 9.4.7. Italy Sales Analysis
- 9.4.8. Russia Sales Analysis
- 9.4.9. Rest Of Europe Sales Analysis
9.5. Asia Pacific Sales Analysis
- 9.5.1. Overview, Historic and Forecast Sales Analysis
- 9.5.2. Asia Pacific by Segment Sales Analysis
- 9.5.3. Asia Pacific by Country Sales Analysis
- 9.5.4. China Sales Analysis
- 9.5.5. India Sales Analysis
- 9.5.6. Japan Sales Analysis
- 9.5.7. South Korea Sales Analysis
- 9.5.8. Australia Sales Analysis
- 9.5.9. Rest Of Asia Pacific Sales Analysis
9.6. Latin America Sales Analysis
- 9.6.1. Overview, Historic and Forecast Sales Analysis
- 9.6.2. Latin America by Segment Sales Analysis
- 9.6.3. Latin America by Country Sales Analysis
- 9.6.4. Brazil Sales Analysis
- 9.6.5. Argentina Sales Analysis
- 9.6.6. Peru Sales Analysis
- 9.6.7. Chile Sales Analysis
- 9.6.8. Rest of Latin America Sales Analysis
9.7. Middle East & Africa Sales Analysis
- 9.7.1. Overview, Historic and Forecast Sales Analysis
- 9.7.2. Middle East & Africa by Segment Sales Analysis
- 9.7.3. Middle East & Africa by Country Sales Analysis
- 9.7.4. Saudi Arabia Sales Analysis
- 9.7.5. UAE Sales Analysis
- 9.7.6. Israel Sales Analysis
- 9.7.7. South Africa Sales Analysis
- 9.7.8. Rest Of Middle East And Africa Sales Analysis

10 . COMPETITIVE LANDSCAPE OF THE PSORIATIC ARTHRITIS THERAPEUTICS COMPANIES

10.1. Psoriatic Arthritis Therapeutics Market Competition
10.2. Partnership/Collaboration/Agreement
10.3. Merger And Acquisitions
10.4. New Product Launch
10.5. Other Developments

11 . COMPANY PROFILES OF PSORIATIC ARTHRITIS THERAPEUTICS INDUSTRY

11.1. Top 10 Company Share Analysis
11.2. Market Concentration Rate
11.3. AbbVie Inc.
- 11.3.1. Company Overview
- 11.3.2. Company Revenue
- 11.3.3. Products
- 11.3.4. Recent Developments
11.4. Janssen Pharmaceutical NV
- 11.4.1. Company Overview
- 11.4.2. Company Revenue
- 11.4.3. Products
- 11.4.4. Recent Developments
11.5. Novartis AG
- 11.5.1. Company Overview
- 11.5.2. Company Revenue
- 11.5.3. Products
- 11.5.4. Recent Developments
11.6. Amgen Inc.
- 11.6.1. Company Overview
- 11.6.2. Company Revenue
- 11.6.3. Products
- 11.6.4. Recent Developments
11.7. Celgene Corporation
- 11.7.1. Company Overview
- 11.7.2. Company Revenue
- 11.7.3. Products
- 11.7.4. Recent Developments
11.8. Eli Lilly and Company
- 11.8.1. Company Overview
- 11.8.2. Company Revenue
- 11.8.3. Products
- 11.8.4. Recent Developments
11.9. Bristol Myers Squibb
- 11.9.1. Company Overview
- 11.9.2. Company Revenue
- 11.9.3. Products
- 11.9.4. Recent Developments
11.10. UCB S.A
- 11.10.1. Company Overview
- 11.10.2. Company Revenue
- 11.10.3. Products
- 11.10.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

簡介目錄圖表